Clinical Trial Update: Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating cabozantinib or sunitinib malate in patients with metastatic variant histology renal cell carcinoma, including several RCC sub…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chromophobe Renal Cell Carcinoma
• Papillary Renal Cell Carcinoma
• Renal Cell Carcinoma
• Renal Cell Carcinoma Associated with Xp11 Translocations Tfe3 Gene Fusions
• Sarcomatoid Renal Cell Carcinoma
• Unclassified Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)
• cabozantinib (cabozantinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING